Key Stats for Eli Lilly Stock
- Current Price: $1,208.12
- Target Price (Mid): ~$2,100
- Street Target: ~$1,223
- Potential Total Return: ~74%
- Annualized IRR: ~13% / year
- Earnings Reaction: +3.07% (April 30, 2026)
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Eli Lilly and Company (LLY) spent most of 2026 fighting a single bearish idea: that the government would squeeze GLP-1 pricing until the growth math stopped working. On June 26, the government moved in a way that cut against that fear. Lilly stock closed up 7.13% at $1,208.12, its best single session in months, after two pieces of news landed within hours of each other. The market had been bracing for pricing to be the villain. Instead, an access expansion put the volume side of the story back in focus.
That is the tension worth sitting with. For six months, bears argued that every concession Lilly made on price would bleed margin faster than volume could refill it. A new Medicare program complicates that frame, because it widens the door for new patients rather than narrowing the price. One caveat up front: the program is not Lilly-specific, and Lilly was not the only pharma name higher on the day, so part of the move was a friendly tape across large-cap pharma. The question for Lilly specifically is how many of those new patients it captures, and whether the stock’s premium valuation was pricing in the policy headwind instead of this tailwind.
A Medicare program just widened GLP-1 access, and Lilly has two drugs in it
The bigger of the two catalysts was access. Starting July 1, 2026, the Centers for Medicare and Medicaid Services launches the Medicare GLP-1 Bridge, a demonstration program that lets eligible Medicare Part D members get certain weight-loss drugs for a flat $50 monthly copay through December 31, 2027. According to CMS, the covered list includes Lilly’s Zepbound (in the KwikPen format) and Foundayo, the company’s oral GLP-1 pill, alongside Novo Nordisk’s Wegovy. That last point matters: this is an industry-wide program run by the government, not a Lilly exclusive, so the read-through is shared with Novo.
What makes it a Lilly story is the share of shelf. Lilly has two of the covered products, including the only oral pill in the group besides Novo’s. The addressable pool is large. One estimate cited by Healthline puts the number of Medicare Part D beneficiaries who could qualify, based on body weight and related conditions, at roughly 14 million. Medicare has historically excluded weight-loss drugs from coverage, so this is a new channel, not a reshuffling of an existing one. The $50 copay also stays flat as a patient moves to higher maintenance doses, which removes the affordability cliff that pushes many people off these drugs within a year.
This is exactly the lever Lilly’s management told investors it was pulling. At the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, where Lilly shared its investor relations materials, Mike Czapar laid out the launch sequence directly. “Beginning in June, we had coverage in all 3 of the pharmacy benefit managers. And then beginning on July 1, we actually have access as part of the Medicare GLP bridge program,” he said. That matters because it confirms the Medicare channel was a scheduled step in Lilly’s plan, not a surprise. The company built the commercial machine first and timed the access switch to flip right as awareness peaked. The risk worth naming: the Bridge is temporary, set to expire at the end of 2027 unless a successor program replaces it.
See historical and forward estimates for Eli Lilly stock (It’s free!) >>>
An EU cancer nod reminded the market Lilly is more than obesity
The second catalyst was quieter but strategically useful. On June 25, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion for Jaypirca (pirtobrutinib), Lilly’s blood-cancer drug, recommending its use for adults with chronic lymphocytic leukemia (CLL, a slow-growing cancer of the white blood cells) across all lines of therapy. A positive opinion is a recommendation, not a final approval. The opinion now goes to the European Commission, with a decision expected within one to two months. Lilly has filed the same data with the U.S. FDA, where a CLL decision is anticipated in the second half of 2026.
The clinical case rests on two trials, BRUIN CLL-313 and CLL-314, that Lilly says were the first Phase 3 studies to test a non-covalent BTK inhibitor, a targeted oral drug that blocks a protein driving cancer-cell growth, in previously untreated CLL patients. For investors, the read-through is about diversification. As Kenneth Custer, EVP and president of Lilly Cardiometabolic Health, put it at Goldman, the core business “generates cash flows that we can then go back and reinvest into future avenues of growth.” The Jaypirca nod is a small, concrete example of that engine producing wins outside the GLP-1 franchise, which is the single best answer to the “one-trick pony” worry that hangs over the stock.
Why the market reaction made sense
The 7% pop was rational because it resolved an asymmetry. Lilly’s whole 2026 narrative had been business strength fighting policy fear, and the stock had lagged its own fundamentals for months as a result. Revenue grew 44.7% in 2025, and the company has beaten consensus revenue every quarter for the past year, with the most recent quarter beating estimated revenue by 11.15%, per TIKR’s Beats and Misses data. Yet the stock reacted only +3.07% to that April 30 print because investors kept discounting the policy overhang.
The Medicare news did not change a single financial in Lilly’s filings. What it changed was the probability that the volume side of the equation wins. Lilly’s own management has argued this dynamic repeatedly: lower prices expand volume in a way that more than offsets the per-unit hit, because the manufacturing base is largely fixed cost. A government program that subsidizes the copay for millions of potential patients is a clean test of that thesis, even shared with Novo.
Against peers, the premium still demands scrutiny. Lilly trades at around 32 times next-twelve-month (NTM, the forward year) price-to-earnings, per TIKR. Johnson & Johnson sits near 22 times and Merck near 21 times on the same basis, while Novo Nordisk, Lilly’s closest GLP-1 rival, trades at roughly 16 times. The peer median across TIKR’s pharmaceutical Competitors page is under 12 times. That is a steep premium, and it is only justified if Lilly’s volume growth keeps outrunning the sector. The access expansion is the kind of event that makes the premium easier, not harder, to defend, because it widens the patient funnel that the entire bull case depends on.
See how Eli Lilly performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $1,208.12
- Target Price (Mid): ~$2,100
- Potential Total Return: ~74%
- Annualized IRR: ~13% / year
See analysts’ growth forecasts and price targets for Eli Lilly stock (It’s free!) >>>
Using TIKR’s mid-case scenario, the model targets around $2,100 for Lilly stock, realized at December 31, 2030, implying a total return of around 74% and an annualized return of around 13% per year over the next 4.5 years. Note the horizon difference behind the headline: the Street’s mean target of around $1,223 sits roughly flat to today’s price because analyst targets typically look twelve months out, while the model runs a multi-year path. The mid case is the right anchor here because it leans on volume and margin assumptions that the Medicare news makes more credible, rather than requiring a heroic pricing outcome.
Two revenue drivers carry the forecast. The first is sustained GLP-1 volume growth from Mounjaro and Zepbound, now reinforced by the Medicare access channel opening July 1. The second is Foundayo’s ramp into the oral obesity market, where early prescriptions skewed heavily toward patients new to the category, suggesting it expands the market rather than cannibalizing the injectables. The margin driver is operating leverage: as Custer’s team scales a largely fixed manufacturing base, net income margin is modeled to expand toward around 43% in the mid case.
The upside is that the Medicare funnel plus oral adoption pushes volume well past the model’s around 12% revenue CAGR assumption, and the stock compounds on earnings alone even with slight multiple compression. The downside is that net realized price falls faster than volume climbs, and a premium valuation with no cushion re-rates lower on any quarter that misses the sky-high bar.
Conclusion
The thesis now has a clean test with a date on it. Watch Foundayo’s weekly prescription run rate and any early Medicare Bridge uptake commentary at Lilly’s next earnings call, scheduled for August 6, 2026. Good looks like Foundayo scripts accelerating into the back half of the quarter as the July 1 access switch and full TV advertising compound, with management quantifying early Bridge enrollment. Bad looks like flat script growth that suggests the access expansion is not converting, which would hand the pricing bears their proof and put the premium multiple under real pressure. The June 26 move bought Lilly the benefit of the doubt. August is when it has to show the patients who actually showed up.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Eli Lilly?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Eli Lilly, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Eli Lilly alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Eli Lilly on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
